top of page
Our Blog
See below for an opinion on current matters around the world.
Search


The ‘Canberra Hypothesis' 50 years on: what can we learn about the pricing and economics of the pharmaceutical industry?
Brendan Shaw The Australian Academy of Science Building (the 'Shine Dome'), Canberra, Australia. Source: Wikimedia Commons . “ It...
Brendan Shaw
Jul 16 min read


It’s not easy being green: environmental sustainability in health systems, health industries and health economics
Brendan Shaw “We are on the front lines.” -            St Vincent and Grenadine’s Prime Minister Ralph Gonsalves, July 2024 .   “Part of...
Brendan Shaw
Jul 25, 20248 min read


Have health and the PBS come of age as the Intergenerational Report turns 21?
Brendan Shaw Article published in Biopharmadispatch, 28 August 2023, (paywall) which can be found here. #medicines #ageing #economics...
Brendan Shaw
Aug 27, 20231 min read


The 2023 WHO Essential Medicines List & The Importance of Industry Engagement
Brendan Shaw Article published in PharmaBoardroom 8 August 2023 can be found here: https://pharmaboardroom.com/articles/the-2023-who-esse...
Brendan Shaw
Aug 8, 20231 min read


The rise of India's pharmaceutical sector
Ambrish Singh & Brendan Shaw "The Indian pharmaceutical industry has been a key aspect for the Indian economy." - Indian Prime Minister,...
Brendan Shaw
Nov 22, 20216 min read


What future from a ‘no-deal’ Brexit for UK life sciences?
Brendan Shaw and Sunayana Shah With the Brexit negotiations between the United Kingdom and the European Union at an impasse and rising...
Brendan Shaw
Sep 12, 20206 min read


New industrial policy for biopharmaceutical and devices industry needs careful thought
Article published in BioPharmaDispatch on 17 April 2020 about the debate in Australia on expanding national manufacturing capacity in...
Brendan Shaw
Apr 16, 20201 min read


What trade war?: Western and Chinese life science companies just get on with it
"When the winds of change blow, some people build walls and others build windmills" - Chinese proverb There’s been a lot said about the...
Brendan Shaw
Dec 4, 20195 min read


Biopharmaceutical industry comes through in dealing with Ebola
Recent news that two new drugs to treat the Ebola virus developed by the biopharmaceutical industry have achieved a 90% cure rate is...
Brendan Shaw
Sep 1, 20194 min read


History Repeats with the Release of the 2019 WHO Essential Medicines List
Article published in PharmaBoardroom on 2 August 2019. The article can be found here: https://pharmaboardroom.com/articles/history-repeat...
Brendan Shaw
Aug 3, 20191 min read


Australia's National Medicines Policy is outdated and in need of review
Article published with Associate Professor Orin Chisholm from the University of New South Wales on 22 July 2019 in the Medical Journal of...
Brendan Shaw and Orin Chisholm
Jul 23, 20191 min read


HTA 2.0: time for a reboot
A few days spent at the Health Technology Assessment International (HTAi) 2019 conference in Cologne this week gave a sense of how the...
Brendan Shaw
Jun 20, 20195 min read


UHC and medicine price transparency feature at 2019 World Health Assembly
The 2019 World Health Assembly in Geneva, the 72nd such meeting, as always covered many important health issues from around the world. A...
Brendan Shaw and Siddhartha Prakash
May 30, 20196 min read


Reflections on the art of political campaigning and advocacy
Deciding if, how and when to engage in an election campaign for an industry association like Medicines Australia probably is more art...
Brendan Shaw
May 12, 20191 min read


Alzheimer's failure a lesson in why pharma companies are vital
News that a joint research project by pharmaceutical companies Biogen and Eisai to develop a new drug to treat Alzheimer's Disease has...
Brendan Shaw
Apr 18, 20192 min read


The WHO’s Essential Medicines List: Changing the Conversation
Article published in Pharma Boardroom on how a new approach to the WHO’s Essential Medicines List is needed to ensure both the patients...
Brendan Shaw
Mar 31, 20191 min read


Universal health coverage and health technology assessment in Sub-Saharan Africa
" Africa's progress, if it is noticed at all, is seen as an improbable stroke of good fortune, a temporary break from its impoverished...
Brendan Shaw
Oct 3, 20185 min read


Access Accelerated: NCDs and the pharmaceutical industry’s coming of age
“Premature death from noncommunicable diseases (NCDs) continues to be one of the major development challenges in the 21st century” -      ...
Brendan Shaw
Sep 21, 20185 min read


Can we handle a cure?: the politics and economics of hepatitis C treatment
When the first of the new hepatitis C medicines, the direct acting antivirals (DAAs), entered the market about five years ago they became...
Brendan Shaw
Jul 27, 20185 min read


To price or not to price, that is the question
What price to put on a medicine is one of the big issues in global health right now. While there are times when the debate around drug...
Brendan Shaw
Jun 28, 20185 min read
bottom of page
